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Challenges to Data Monitoring Committees When Regulatory 
Authorities Intervene
Karl Swedberg, M.D., Ph.D., Jeffrey S. Borer, M.D., Bertram Pitt, M.D., Stuart Pocock, Ph.D.,  
and Jean Rouleau, M.D.
New pharmaceutical agents are best evaluated in 
randomized, controlled clinical trials in which 
both the safety of participants and the adequacy 
of conduct are monitored by an independent data 
monitoring committee as described in reports 
from regulatory organizations.1-3 A data monitor-
ing committee can recommend discontinuation 
of a trial because of futility or because of over-
whelming benefit or unacceptable harm associ-
ated with an agent, and it can recommend modi-
fication of a trial for safety. The data monitoring 
committee should review relevant contributory 
information from parallel studies4-8 in order to 
make appropriate recommendations.
Regulatory authorities also must evaluate trial 
data, but they should not interfere in the conduct 
of the trial if an independent data monitoring 
committee determines that the progress of the 
trial is appropriate and no modification is re-
quired for safety. Here we report our recent expe-
rience with a regulatory action that we consider 
to be a threat to the function of data monitoring 
committees and potentially to the integrity of 
monitored trials.
The renin inhibitor aliskiren was approved for 
use in patients with hypertension in the United 
States in 2005 and in the European Union in 
2007. We were the data monitoring committee 
for both the Aliskiren Trial on Acute Heart Fail-
ure Outcomes (ASTRONAUT), which evaluated 
the effects of aliskiren in addition to an angio-
tensin-converting–enzyme (ACE) inhibitor or 
angiotensin-receptor blocker (ARB) in patients 
with acute heart failure,9 and the Aliskiren Trial 
to Minimize Outcomes in Patients with Heart 
Failure (ATMOSPHERE), which compared three 
treatments (enalapril, aliskiren, and a combina-
tion of these two agents) in patients with chron-
ic heart failure.10
In December 2011, when recruitment to 
 ASTRONAUT was closed, a third trial, the Aliski-
ren Trial in Type 2 Diabetes Using Cardiorenal 
Endpoints (ALTITUDE), was terminated because 
the excess risk of adverse events with aliskiren 
outweighed any potential benefits (Fig. 1). At the 
time, 69% of the projected events had occurred.11 
ALTITUDE was conducted in patients with type 2 
diabetes and chronic kidney disease, chronic car-
diovascular disease, or both; like ASTRONAUT, it 
evaluated aliskiren in addition to either an ACE 
or an ARB.
The ALTITUDE findings raised concern about 
the potential for adverse effects of aliskiren in 
other trials, especially in patients with diabetes. 
In January 2012, the German Federal Institute 
for Drugs and Medical Devices (BfArM) asked 
the chair of the data monitoring committee 
about the effects of aliskiren in patients with 
diabetes in the two trials we monitored.
At the time of the BfArM inquiry, the most 
recent safety report of the ASTRONAUT data 
monitoring committee, from December 2011, 
included 1430 patients who had undergone ran-
domization (89% of the projected total), of whom 
42% had diabetes. The average follow-up was 
7 months. In patients with diabetes, renal dys-
function had developed in 14.1% of the patients 
receiving aliskiren, as compared with 10.2% re-
ceiving placebo. The trial results were neutral 
with respect to the primary end point (death 
from cardiovascular causes or rehospitalization 
within 6 months), but only two thirds of the 
reported events had been adjudicated.
We reassured the BfArM that the ALTITUDE 
findings would be considered in our recommen-
dations for trial conduct in ASTRONAUT. To 
maintain the integrity of the trial, however, we 
would not release the ASTRONAUT data we were 
monitoring. At our March 2012 review, the De-
cember pattern of events persisted, so we recom-
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mended continuation of the trial to its planned 
completion 4 months later. When the results of 
ASTRONAUT were published,11 among 20 sub-
groups analyzed, there was a significant in-
crease in the rate of primary end-point events 
with aliskiren, as compared with placebo, among 
patients with diabetes at 12 months, but not at 
6 months, and there was a significant reduction 
in this rate among patients who did not have 
diabetes.12
The December 2011 safety report of the 
 ATMOSPHERE data monitoring committee in-
cluded 5441 patients, of whom 1581 had diabetes. 
In the combination-therapy group, patients with 
diabetes had significantly more renal dysfunc-
tion and hyperkalemia than did patients without 
diabetes, and these conditions were associated 
with a higher rate of primary-composite-outcome 
events (deaths from cardiovascular causes or hos-
pitalizations for heart failure). However, these 
events were relatively infrequent, and there 
were slightly fewer primary composite events in 
the combination-therapy group than in either of 
the single-therapy groups both in patients with 
diabetes and in those without diabetes.
After the BfArM inquiry, we again reviewed 
Figure 1. Timeline of the Progress of the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE), 
the Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT), and the Aliskiren Trial to Minimize Outcomes 
in Patients with Heart Failure (ATMOSPHERE).
BfArM denotes German Federal Institute for Drugs and Medical Devices, CTFG Clinical Trial Facilitation Group, 
and DMC data monitoring committee.
2009
2010
2011
2012
2013
2014
2015
2016
Dec. 2011 Trial discontinued for
excess risk of adverse events
Nov. 2012 Trial results published
July 2015 Trial completed
May 2009 First patient enrolled
Jan. 2012 Request from BfArM
to share unblinded data
March 2012 Monthly review
of long-term consequences
of renal dysfunction initiated
Feb. 2013 Request by CTFG to 
discontinue aliskiren in patients
with diabetes
April–May 2013 Aliskiren discon-
tinued in patients with diabetes
Dec. 2013 Last patient underwent
randomization
March 2015 Last DMC review
April 2016 Trial results published
March 2009 First patient enrolled
Dec. 2011 Last patient underwent
randomization
Jan. 2012 Request from BfArM
to share unblinded data
March 2012 Last DMC review
March 2013 Published trial results 
show increase in rate of primary 
end-point events among patients
with diabetes
July 2012 Trial completed
ALTITUDE ASTRONAUT ATMOSPHERE
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ATMOSPHERE 4 months later, taking into ac-
count both the ALTITUDE and the ASTRONAUT 
results. We found no change in patterns of 
events and no reason to alter the trial. We also 
investigated whether patients with renal dysfunc-
tion (both in patients with diabetes and in those 
without diabetes) had any excess of adverse 
clinical outcomes, including deaths from non-
cardiovascular causes. These results were updated 
monthly and provided to the chair of the data 
monitoring committee. No excess of adverse 
outcomes was found.
In February 2012, the ATMOSPHERE data 
monitoring committee recommended continua-
tion of the trial despite the ALTITUDE results; 
this recommendation was accepted by the execu-
tive committee of the trial. In April 2012, BfArM 
requested more frequent safety reviews by the 
data monitoring committee than the number of 
reviews mandated by the trial protocol and char-
ter. The data monitoring committee had already 
increased the frequency of reviews; was monitor-
ing patients with diabetes, renal dysfunction, 
or both with more detailed analyses; and found 
that the previously observed differences in the 
consequences of renal events among the treat-
ment groups had disappeared. No new concerns 
were identified and, in the overall population, 
the effects on the primary outcome continued to 
be numerically lowest in the combination-therapy 
group.
The January 2013 review of 6381 randomly 
assigned patients in ATMOSPHERE further re-
assured the data monitoring committee of the 
overall safety of combination therapy, since no 
new safety issues were identified. There were 
numerically fewer hospitalizations for heart fail-
ure, deaths from cardiovascular causes, myocar-
dial infarctions, and strokes with combination 
therapy than with enalapril alone, and there was 
a significant benefit of combination therapy with 
respect to the primary end point. Our unanimous 
recommendation to the sponsor and executive 
committee was to continue ATMOSPHERE ac-
cording to the protocol.
In February 2013, on the basis of data from 
ALTITUDE and ASTRONAUT, but without knowl-
edge of the unblinded ATMOSPHERE results, 
the Clinical Trial Facilitation Group of the Euro-
pean Union requested that the sponsor of 
 ATMOSPHERE, Novartis, discontinue administra-
tion of aliskiren in all patients with diabetes in 
ATMOSPHERE. The data monitoring committee 
had already informed BfArM that it had consid-
ered the results of ALTITUDE and ASTRONAUT 
when recommending that ATMOSPHERE con-
tinue as planned and was conducting careful 
analyses regarding patients with diabetes. The 
sponsor and executive committee expressed con-
fidence in the data monitoring committee. How-
ever, in accordance with the mandate of the 
Clinical Trial Facilitation Group, administration 
of aliskiren was discontinued in patients with 
diabetes in April and May 2013 and follow-up 
data on these patients were censored at the time 
of discontinuation of aliskiren. This resulted in 
the need to prolong ATMOSPHERE by 1 year to 
meet event targets.
In March 2015, when randomization was com-
plete, the data monitoring committee conducted 
its last data review and recommended continua-
tion of the trial to its planned ending in July 
2015. The article by McMurray et al. now pub-
lished in the Journal reports the final trial re-
sults.13 The report indicates that there was no 
significant difference in the primary trial out-
come or in the outcome of death from any cause 
among the three trial groups. There was also no 
evidence of a differential effect of aliskiren or of 
combination therapy in patients with diabetes 
as compared with those without diabetes.
Concerns regarding the effect of reported ex-
ternal evidence on interventions evaluated in on-
going clinical trials have been well documented.5,8 
When the strength of external evidence is indis-
putable and the pathophysiologic processes are 
similar to those in the ongoing trial, the impact 
of these findings generally should be immedi-
ate, with a prompt change in the trial protocol to 
reflect the concerns raised. If the strength and 
relevance of the external data are less decisive, 
reliance on the judgment of the data monitoring 
committee is appropriate, since it is this commit-
tee that is tasked with considering the totality of 
evidence in monitoring the ongoing trial.
Given the results of ALTITUDE and 
 ASTRONAUT, the concerns of the regulators 
regarding patients in ATMOSPHERE were reason-
able. However, it is noteworthy that ATMOSPHERE 
had a run-in period that helped to identify pa-
tients who could not receive enalapril or aliski-
ren without unacceptable adverse events; these 
 patients then were excluded from randomiza-
tion and long-term treatment. ALTITUDE and 
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ASTRONAUT had no such run-in period. Another 
potential contributor to the differences found is 
the patient population studied, since dual renin–
angiotensin system blockade has not been shown 
to produce an additional benefit over single 
blockade in patients without heart failure,14 but 
it may be useful in patients with heart failure.15 
In addition, multiple interventions that have 
proved to be of benefit in patients with chronic 
heart failure have not been beneficial in patients 
with acute heart failure.
In the future, we recommend that regulators 
consider the following course of action before 
requesting discontinuation of a study drug in 
patients in an ongoing trial as a result of emerg-
ing data from other trials. Regulators could re-
quest special attention to particular populations, 
such as those with diabetes in ATMOSPHERE, 
and request that the analysis plan of the data 
monitoring committee be extended. The data 
monitoring committee’s statistical analysis plan 
to deal with such concerns could be shared with 
regulators to reassure them that the safety of 
potentially vulnerable patients is being properly 
assessed. The provision of this plan could be 
combined with a formal written statement from 
the data monitoring committee to the regulators 
after each meeting of the data monitoring com-
mittee; this statement would reiterate that the 
trial should continue as planned. Whether pa-
tients should be asked to provide additional in-
formed consent after being informed of the new 
external evidence would depend on the strength 
and applicability of the evidence.
The course of action proposed by BfArM — 
that the data monitoring committee share un-
blinded data from ATMOSPHERE with the agency 
— is problematic. It could compromise the integ-
rity of the trial, particularly if regulators in each 
country made the same request, thereby causing 
wider release of unblinded data. Sharing of un-
blinded data from ongoing blinded trials with 
several regulators could lead to a variety of inter-
pretations, with consequent confusion about what 
appropriate measures should be taken to ensure 
patient safety.
We strongly recommend that the data moni-
toring committee in a clinical trial be allowed to 
act independently during the progress of the 
trial. If legitimate concerns arise regarding the 
safety of any intervention, as was the case here, 
sharing of data with regulators should be avoided. 
In special cases, the data monitoring commit-
tee’s statistical analysis plan to deal with these 
concerns should be shared with the regulators. 
A collective trust in the key responsibilities of 
the data monitoring committee is essential. We 
note that the sponsor and the regulatory agen-
cies involved have written letters of reply (now 
published in the Journal) in response to our 
concerns,16,17 and we appreciate their interest in 
supporting efforts to prevent future problems of 
this kind.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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